Phase I trials of the lysine-specific demethylase 1 inhibitor, GSK2879552, as mono- and combination-therapy in relapsed/refractory acute myeloid leukemia or high-risk myelodysplastic syndromes

Autor: Gail J. Roboz, Karen Yee, Amit Verma, Gautam Borthakur, Adolfo de la Fuente Burguera, Guillermo Sanz, Helai P. Mohammad, Ryan G. Kruger, Natalie O. Karpinich, Geraldine Ferron-Brady, Andre Acusta, Heather Del Buono, Therese Collingwood, Marc Ballas, Arindam Dhar, Andrew H. Wei

Publikováno v: Leukemia & Lymphoma. 63:463-467

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::06962155665e6e769eb21bfa46208fc3
https://doi.org/10.1080/10428194.2021.2012667

Phase I trials of the lysine-specific demethylase 1 inhibitor, GSK2879552, as mono- and combination-therapy in relapsed/refractory acute myeloid leukemia or high-risk myelodysplastic syndromes

Autor: Roboz GJ, Yee K, Verma A, Borthakur G, de la Fuente Burguera A, Sanz G, Mohammad HP, Kruger RG, Karpinich NO, Ferron-Brady G, Acusta A, Del Buono H, Collingwood T, Ballas M, Dhar A, Wei AH

Publikováno v: Leukemia & lymphoma
r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe
instname

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=RECOLECTA___::e2923b92cf4577c43228ce6e5e3bac1e
https://fundanet.iislafe.san.gva.es/publicaciones/ProdCientif/PublicacionFrw.aspx?id=15262

Impact of a Weekly GLP-1 Receptor Agonist, Albiglutide, on Glycemic Control and on Reducing Prandial Insulin Use in Type 2 Diabetes Inadequately Controlled on Multiple Insulin Therapy: A Randomized Trial

Autor: Philip Home, Jason Mallory, Molly C. Carr, Jo Dole, Andre Acusta, Lois Erskine, Joseph Soffer, Antonio Nino, Julio Rosenstock

Objective: The principle of replacing prandial insulin lispro with a once-weekly GLP-1 receptor agonist (GLP-1RA) in type 2 diabetes inadequately controlled on a multiple daily insulin injections regimen was tested with albiglutide. Research Design a

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::5c4d0c0fd11e4c8fc7a42d64fcea7e61
https://doi.org/10.2337/figshare.12469121.v1

Near-Normoglycemia, with Meaningful Discontinuations of Prandial Insulin, by Adding Weekly Albiglutide (Albi) to Uncontrolled Basal/Bolus Insulin-Treated Type 2 Diabetes (T2DM)

Autor: Julio Rosenstock, Philip Home, Molly C. Carr, Andre Acusta, Antonio Nino, Jo F. Dole, Jason M. Mallory, Lois M. Erskine, Joseph Soffer

Publikováno v: Diabetes. 67

The glycemic efficacy of weekly Albi 50 mg to replace prandial insulin lispro (Lis) was evaluated in T2DM inadequately controlled on a multiple daily insulin regimen (≥3 injections/day). Basal/bolus insulin was optimized during a 4 week run-in phas

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::20a2c0f0386d8d7d170151a309901cfb
https://doi.org/10.2337/db18-1073-p

A phase I/II study of GSK3145095 alone and in combination with anticancer agents including pembrolizumab in adults with selected solid tumors

Autor: Deirdre Jill Cohen, Justin Callaway, Jill M. Marinis, James F. Smothers, Shubham Pant, Chetan Rathi, Andre Acusta, John Bertin, Bert H. O'Neil, Christoph M. Ahlers, James Winnberg, Adeline Verticelli

Publikováno v: Journal of Clinical Oncology. 37:TPS4165-TPS4165

TPS4165 Background: The immunosuppressive myeloid infiltrate characteristic of the tumor microenvironment in pancreatic cancer represents a major therapeutic barrier in this disease. Modulation of this infiltrate may increase sensitivity to immune ch

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::93360b22a96e697c006aa1c968ef29a2
https://doi.org/10.1200/jco.2019.37.15_suppl.tps4165